BRAF and lung adenocarcinoma: In addition to epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase gene alternations, genomic studies in lung adenocarcinoma have identified other potential therapeutic targets, including activating mutations in Kras, BRAF, HER2 and PIK3CA, in frequencies >1% (4–6).